Top Life Sciences Attorney to Join Intrexon as Chief Legal Officer

Top Life Sciences Attorney to Join Intrexon as Chief Legal Officer

Asher M. Rubin to oversee all legal affairs of industry-leading biotech company

BLACKSBURG, Va.--(BUSINESS WIRE)--Intrexon Corporation, a privately held life sciences company focused on modular DNA control systems for biotherapeutics and other industry sectors, today announced the appointment of Asher M. Rubin as Executive Vice President, Chief Legal Officer, and Secretary. Mr. Rubin will be based at Intrexon's corporate offices in Montgomery County, Maryland.

Mr. Rubin joins Intrexon from Hogan & Hartson, LLP, where he is a Partner in the Corporate and Securities Group in the Baltimore, Maryland office. He also chaired the firm's multidisciplinary Life Sciences Practice Group. Mr. Rubin's career has focused on the life sciences industry and regularly included U.S. Securities and Exchange Commission reporting, complex financings, mergers and acquisition, and corporate governance matters. Prior to joining Hogan & Hartson, Mr. Rubin served as senior vice president, general counsel, and secretary for Guilford Pharmaceuticals Inc. where he was responsible for all of the company's legal matters. Mr. Rubin is a graduate of Duke University and the University of Maryland School of Law where he received awards and national recognition for his advocacy skills. He is a member of the Maryland State Bar Association and has been an active leader in numerous life sciences professional organizations and their proceedings, including the Biotechnology Industry Organization (BIO), Law Seminars International (Biotechnology), the BNA Life Sciences Law & Industry Report and the American Society of Corporate Secretaries & Governance Professionals.

"Asher is an outstanding attorney who has been practicing at the top-tier of life sciences corporate and legal affairs for over a decade," stated Randal J. Kirk, Intrexon's Chairman and CEO. "He brings to Intrexon not only his exceptional talents, but also a very current perspective on a range of important life sciences issues and solutions that are highly relevant to our multi-vertical commercialization strategy. I look forward to working closely with Asher as we continue to accelerate Intrexon's upward trajectory and navigate many industry-shaping transactions."

Mr. Rubin also emphasized the currency of his life sciences experience and its application to Intrexon's strategy. "The opportunity to join Intrexon has intersected my career at an ideal moment," he said, "I have been actively involved in a wide range of life sciences transactions and matters that are, in total, reflected throughout Intrexon's various strategic initiatives and apparent upside momentum. I can think of no other company poised similarly in our industry and am most eager to contribute my part to this passionate and dedicated team of executive leaders."

About Intrexon Corporation

Intrexon Corporation is a privately held life sciences company that employs modular DNA control systems to enhance capabilities, improve safety and lower cost in human therapeutics, protein production, industrial enzymes and ag/bio. The company's advanced transgene engineering platform enables a new level of biotech - combining breakthroughs in DNA control systems with corresponding advancements in modular transgene design, assembly and optimization. The company is currently using these advanced capabilities to solve foremost challenges across the life sciences spectrum. More information about the company is available at www.DNA.com.

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Scientists at McMaster University and the University of Toronto have formed Empirica Therapeutics to bring a CAR-T for glioblastoma into the clinic.